Platinum-resistant Ovarian Cancer Completed Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs